Anthos Therapeutics, Inc.

This phase 2 study compares abelacimab, a new biologic blood thinner, to the standard drug rivaroxaban in 1,287 people with atrial fibrillation who are at moderate-to-high risk of stroke. The goal is to see if abelacimab causes fewer major or clinically relevant bleeding events w…